Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Aura Biosciences, Inc.NASDAQ: AURA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$274K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$574K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$274K or moves back toward the trailing-twelve-month quarterly average of -$143.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$274K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$574K-97.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.3% is the 9th highest of 10, against a peer median of +94.3%.
AURA Competitors
Gross Profit for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
AKTSAktis Oncology, Inc.FY2025$6.5M USD+336.9%—100.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$5.83M USD-88.9%-4.0%76.5%
OCGNOcugen, Inc.LTM Mar 2026$4.47M USD-1.3%-6.6%100.0%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K USD+100.0%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
AURAAura Biosciences, Inc.LTM Mar 2026-$574K USD-97.3%——
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M USD-4457.3%—360.9%
BCYCBicycle Therapeutics plcLTM Mar 2026-$7.53M USD+94.3%+71.2%11.9%
OCSOculis Holding AGLTM Mar 2026-CHF 14.56M CHF——2889.4%
Peer median (excluding AURA) —+94.3%-5.3%100.0%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.3M00
Gross Profit00(1.3M)00
Gross Margin—————
Research & Development25.16M42.24M63.94M73.3M90.3M
Selling, General & Admin10.09M18.06M19.76M22.81M22.49M
Operating Expenses35.25M60.3M83.7M96.12M112.79M
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
EBITDA(34.41M)(57.59M)(74.98M)(85.58M)(104.95M)
EBITDA Margin—————
Operating Income(35.25M)(60.3M)(84.99M)(96.12M)(112.79M)
Operating Margin—————
Interest Income13K1.86M8.59M9.43M6.63M
Interest Expense13K0000
Other Income / Expenses(1K)1.53M8.72M9.31M6.71M
Income Before Tax(35.25M)(58.76M)(76.27M)(86.81M)(106.08M)
Pre-Tax Margin—————
Income Tax Expense00137K112K108K
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Net Margin—————
EPS (Basic)(1.58)(1.96)(1.93)(1.75)(1.76)
EPS (Diluted)(1.58)(1.96)(1.93)(1.75)(1.76)
Weighted Avg Shares29.21M29.94M39.62M49.65M60.34M
Weighted Avg Shares (Diluted)29.21M29.94M39.62M49.65M60.34M

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.